研究单位：[1]Tasly Pharmaceuticals,Inc.[2]Beijing Hospital Beijing,Beijing,China[3]Peking Union Medical College Hospital,Chinese Academy of Medical Sciences Beijing,Beijing,China[4]Xuanwu Hospital Capital Medical University Beijing,Beijing,China[5]Peking University People's Hospital Beijing,Bejing,China[6]The First Affiliated Hospital of Chongqing Medical University Chongqing,Chongqing,China[7]Hebei General Hospital Shijiazhuang,Hebei,China[8]The Third Affiliated Hospital of Xinxiang Medical College Xinxiang,Henan,China[9]The third Xiangya Hospital of Central South University Changsha,Hunan,China[10]Jiangsu Province Hospital Nanjing,Jiangsu,China[11]Zhongda Hospital Southeast University Nanjing,Jiangsu,China[12]China Japan Union Hospital of Jilin University Changchun,Jilin,China[13]The Affiliated Hospital of Inner Mongolia Medical University Hohhot,Nei Monggol Autonomous Region,China[14]First Hospital of Shanxi Medical University Taiyuan,Shanxi,China[15]The Second Affiliated Hospital Of Xi'an Jiaotong University Xi'an,Shanxi,China[16]Tianjin Chest Hospital Tianjin,Tianjin,China
研究目的：
Main objective: To evaluate the efficacy, safety and clinical dose exploration of Qishen Yiqi dripping pills in the treatment of chronic heart failure with preserved ejection fraction.
Exploratory research objective: To explore the changes of endogenous substances in vivo before and after drug administration, to interpret the mechanism of drug action through metabolomics and systems biology methods, and to find potential clinical biomarkers for exploratory subgroup analysis of clinical trials.
